A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis

You likely can't join if

• Participants are excluded from the study if any of the following criteria apply: -Have had a clinically significant flare of psoriasis during the 12 weeks before the baseline visit -Have a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis -Have any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD, or systemic lupus erythematosus -Have a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic immunosuppressant medical treatment -Have any active skin disease other than psoriasis that could interfere with the assessment of psoriasis -Have a current or recent acute, active infection -Have had any of the following types of infection within 3 months prior to the screening visit or develops any of these infections before the randomization visit: •Serious (requiring hospitalization or intravenous or equivalent oral antibiotic treatment) •Opportunistic (Herpes zoster is considered active and ongoing until all vesicles are dry and crusted over) •Chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer) •Recurring (including, herpes simplex, herpes zoster, recurring cellulitis, chronic osteomyelitis) •Have active TB •Have or have had LTBI that has not been treated with a complete course of appropriate therapy, unless such treatment is underway •Have a current infection with HBV or HCV •Have HIV infection -Have a history of malignancy or lymphoproliferative disease -Have previously received a solid organ transplant -Have undergone major surgery within 12 weeks before the first dose of study intervention or such surgery is planned to be performed during the study •Have History or evidence of hepatic impairment, any current serious or unstable illnesses including renal, gastrointestinal, respiratory, cardiovascular, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions, have history of significant allergies to lidocaine or other topical anesthetics -Are actively suicidal and therefore deemed to be at significant risk for suicide -History of a suicide attempt within the 5 years prior to the Screening Visit. -Have answered “yes” to either Question 4 or Question 5 on the “Suicidal Ideation” portion of the C-SSRS and the ideation occurred within the past month OR Have answered “yes” to any of the suicide-related behaviors on the “suicidal behavior” portion of the C-SSRS and the behavior occurred within the past 3 months -Have received any live vaccine within the 6 weeks before the first dose of study intervention, a BCG vaccination or treatment within less than 4 weeks before randomization, or intend to receive BCG vaccination or treatment during the study -Have received any therapeutic agent targeting IL-17 and discontinued the anti IL-17 therapy for any of the following reasons: did not how addecuate response after treatment of at least 3 months and/or lost response after prolonged therapy, intolerability or toxicity, irrespective of treatment duration -Have received any therapeutic agent targeting IL-17within 16 weeks or 5 laf lives before the first dose of study intervention - Have received anti-TNFα inhibitor(s) or agents that modulate B cells or T cells within 12 weeks or 5 half-lives before the first dose of study intervention For other exclusion criteria refer to the Protocol